3507 ORAL Sorafenib improves survival in a large multi-center, randomized, placebo-controlled phase III trial in patients with hepatocellular carcinoma — Josep M. Llovet (2007) | RDL Network
3507 ORAL Sorafenib improves survival in a large multi-center, randomized, placebo-controlled phase III trial in patients with hepatocellular carcinoma
European Journal of Cancer Supplements 5(4): 261-261
Josep M. Llovet, Serafino Ricci, Vincenzo Mazzaferro, P Hilgard, Jean‐Luc Raoul, Stefan Zeuzem, Melanie Poulin-Costello, M. Moscovici, D. Voliotis, Jordi Bruix
Josep M. Llovet, María Isabel Real, R. Vilana, Ramón Planas, S. Coll, John J. Aponte, Carmen Ayuso, María Sala, Jordi Muchart, R. Costa, J Rodés, Jordi Bruix
Andrew X. Zhu, Olivier Rosmorduc, T.R. Jeffry Evans, Paul J. Ross, Armando Santoro, Flair José Carrilho, Jordi Bruix, Shukui Qin, Paul J. Thuluvath, Josep M. Llovet, Marie-Aude LeBerre, Markus Jensen, Gerold Meinhardt, Yoon‐Koo Kang
Discussion(0)
No comments yet. Be the first to comment.